Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver symbols : Tak save search
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Published: 2023-04-04 (Crawled : 17:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: -0.12%
H: 1.55%
C: 1.03%
ARWR | $23.25 -2.23% 70K
|
Health Technology
|
| O: 0.67%
H: 0.08%
C: -2.22%
liver disease payment milestone study
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2023-01-09 (Crawled : 13:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 0.13%
H: 0.38%
C: -0.19%
ARWR | $23.25 -2.23% 70K
|
Health Technology
|
| O: -19.61%
H: 3.16%
C: 0.77%
liver disease topline results study
Insights on the Liver Disease Treatment Global Market to 2027 - by Treatment Type, Disease Type, End-user and Region
Published: 2022-04-12 (Crawled : 21:00) - prnewswire.com
GLAXF | News | $19.54 2.6K
|
Health Technology
|
| O: 1.76%
H: 0.35%
C: 0.35%
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: -4.71%
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -0.83%
ALPMY | News | $9.49 480K
|
Manufacturing
|
| O: 2.3%
H: 0.55%
C: 0.36%
VTRS | News A | $11.29 -0.62% 580K
|
Health Technology
|
| O: 0.37%
H: 2.99%
C: 2.61%
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: -0.2%
H: 1.83%
C: 1.83%
NVS | News | $98.03 0.77% 650K
|
Health Technology
|
| O: 0.12%
H: 0.44%
C: 0.17%
GSK | News | $40.82 -1.02% 230K
|
Health Technology
|
| O: -0.24%
H: 0.45%
C: 0.39%
LLY | News | $733.27 -1.67% 470K
|
Health Technology
|
| O: -0.26%
H: 0.33%
C: -1.5%
BMY | $48.795 -0.4% 1.5M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
ABBV | News | $168.635 -0.53% 440K
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
ABT | News | $106.1 -1.39% 810K
|
Health Technology
|
| O: -0.7%
H: 1.91%
C: 1.63%
SNY | News | $47.1 -1.24% 260K
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
treatment liver disease market
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Published: 2022-03-14 (Crawled : 01:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 0.42%
H: 0.48%
C: -0.41%
EXEL | $23.55 1.12% 160K
|
Health Technology
|
| O: 0.0%
H: 1.21%
C: -1.91%
osmic-312 liver trial cancer phase 3
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
Published: 2022-02-03 (Crawled : 08:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 0.55%
H: 1.5%
C: -1.3%
fy2021 liver results
Red Cross delivering comfort and help after deadly tornadoes
Published: 2021-12-12 (Crawled : 20:20) - prnewswire.com
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
NOW | $745.26 0.58% 240K
|
Technology Services
|
| O: -0.78%
H: 2.56%
C: 1.75%
R | News | $120.565 -1.18% 47K
|
Finance
|
| O: -1.06%
H: 3.81%
C: 2.81%
NEE | $65.98 -0.33% 1.6M
|
Utilities
|
| O: 0.2%
H: 2.06%
C: 1.64%
LMT | $456.93 -0.69% 190K
|
Electronic Technology
|
| O: -0.36%
H: 0.7%
C: 0.33%
KMB | $134.67 -1.01% 510K
|
Consumer Non-Durables
|
| O: -0.32%
H: 2.73%
C: 2.4%
F | News | $12.965 0.19% 5.9M
|
Consumer Durables
|
| O: 7.34%
H: 0.0%
C: 0.0%
EIX | $70.36 -0.69% 290K
|
Utilities
|
| O: -0.39%
H: 0.66%
C: 0.15%
AVB 4 | $188.99 0.18% 39K
|
Finance
|
| O: -0.46%
H: 1.86%
C: 1.33%
MO 4 | $42.785 -0.2% 1.4M
|
Consumer Non-Durables
|
| O: 0.02%
H: 1.04%
C: 0.73%
KHC | $37.895 -0.46% 640K
|
Consumer Non-Durables
|
| O: 2.03%
H: 1.67%
C: 0.97%
LHCG | $169.81 0.47% -0.03% 0
|
Health Services
|
| O: 0.51%
H: 1.23%
C: -1.06%
FOXA | News | $31.575 -0.43% 160K
|
Consumer Services
|
| O: -1.3%
H: 0.55%
C: -0.3%
FOX | News | $29.19 0.03% 86K
|
Consumer Services
|
| O: -1.02%
H: 0.56%
C: -0.41%
liver
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
ARWR | $23.25 -2.23% 70K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment liver
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
Published: 2021-10-28 (Crawled : 09:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 2.03%
H: 3.33%
C: 0.07%
brands results growth liver
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
Published: 2021-09-21 (Crawled : 13:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 1.35%
H: 0.58%
C: 0.06%
MIRM | $24.14 -1.15% 24K
|
Health Technology
|
| O: 5.09%
H: 2.63%
C: 0.53%
disease liver disease liver license commercialization rare
Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases
Published: 2021-08-23 (Crawled : 12:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 1.45%
H: 0.95%
C: 0.89%
disease liver disease gene therapies collaboration license liver gene therapy therapy rare
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
Published: 2021-07-30 (Crawled : 09:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
results topline growth liver positive
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 0.0%
H: 0.06%
C: -1.17%
ARWR | $23.25 -2.23% 70K
|
Health Technology
|
| O: 1.95%
H: 1.82%
C: -1.98%
disease liver disease treatment fda therapy breakthrough therapy liver designation
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
Published: 2021-06-28 (Crawled : 09:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 0.24%
H: 0.03%
C: -0.47%
EXEL | $23.55 1.12% 160K
|
Health Technology
|
| O: -13.27%
H: 2.16%
C: -11.28%
cancer phase 3 liver trial
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021
Published: 2021-05-11 (Crawled : 08:00) - biospace.com/
BX | $124.34 0.02% 240K
|
Finance
|
| O: -2.01%
H: 1.74%
C: 1.15%
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: -0.71%
H: 0.45%
C: -0.77%
JNJ | News | $147.885 -1.12% 1.5M
|
Health Technology
|
| O: 0.22%
H: 0.13%
C: -1.04%
results ev growth liver
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Published: 2021-04-28 (Crawled : 13:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: -0.95%
H: 0.84%
C: 0.48%
ARWR | $23.25 -2.23% 70K
|
Health Technology
|
| O: 0.01%
H: 2.92%
C: 1.92%
disease liver disease treatment fibrosis liver
Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
TAK | News | $13.245 -1.01% 120K
|
Health Technology
|
| O: 1.36%
H: 1.12%
C: 0.96%
fibrosis collaboration license liver
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
SYRA | $1.5 51.23% 1M
|
n/a
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
TROO | $1.41 29.36% 280K
|
Manufacturing
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.